-+ 0.00%
-+ 0.00%
-+ 0.00%

Svas Biosana H1 consolidated revenue slips 1.4% to EUR 69.4 million

PUBT·07/31/2026 16:07:38
Listen to the news
Svas Biosana H1 consolidated revenue slips 1.4% to EUR 69.4 million
  • Svas Biosana posted unaudited H1 2026 consolidated revenue of EUR 69.4 million, down 1.4% from H1 2025.
  • Aggregated revenue by business line totaled EUR 70.4 million, down 2.1%; intragroup revenue eliminations were EUR 1 million.
  • Medical rose 4.1% to EUR 5.1 million; Bormia grew 5.2% to EUR 12.2 million.
  • Farmex fell 8.6% to EUR 15.9 million; SVAS declined 3.3% to EUR 11.9 million; Mark Medical slipped 1.6% to EUR 25.3 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Svas Biosana S.p.A. published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.